SPYRE THERAPEUTICS, INC. Investing Cash Flow
SPYRE THERAPEUTICS, INC. (SYRE) reported Investing Cash Flow of -$241.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$297.90M, a 477.10% decline year-over-year.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $56.58M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$247.41M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $25.00M, a 41.51% decline year-over-year.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$143.47M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$353.29M.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$108.39M, a 290.14% decline from fiscal 2022.
- SPYRE THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was $57.01M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$297.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$241.32M 10-Q · filed 2026-08-04 | -$488.73M derived: sum of 3 quarters · filed 2026-08-04 | -$463.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $56.58M 10-Q · filed 2026-05-05 | -$190.83M derived: sum of 2 quarters · filed 2026-05-05 | -$165.83M derived: sum of 3 quarters · filed 2026-05-05 | -$86.83M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$247.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$222.41M derived: sum of 2 quarters · filed 2026-02-19 | -$143.41M derived: sum of 3 quarters · filed 2026-08-04 | -$143.47M 10-K · filed 2026-02-19 |
| 2025-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $104.00M derived: sum of 2 quarters · filed 2026-08-04 | $103.94M 10-Q · filed 2025-11-04 | -$66.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $79.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $78.94M 10-Q · filed 2026-08-04 | -$91.61M derived: sum of 3 quarters · filed 2026-08-04 | -$48.87M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$61.00K 10-Q · filed 2026-05-05 | -$170.60M derived: sum of 2 quarters · filed 2026-05-05 | -$127.86M derived: sum of 3 quarters · filed 2026-05-05 | -$248.38M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$170.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$127.80M derived: sum of 2 quarters · filed 2026-02-19 | -$248.32M derived: sum of 3 quarters · filed 2026-02-19 | -$353.29M 10-K · filed 2026-02-19 |
| 2024-09-30 | $42.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$77.78M derived: sum of 2 quarters · filed 2025-11-04 | -$182.74M 10-Q · filed 2025-11-04 | -$218.01M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | -$120.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$225.48M 10-Q · filed 2025-08-05 | -$260.75M derived: sum of 3 quarters · filed 2026-02-19 | -$358.38M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$104.96M 10-Q · filed 2025-05-08 | -$140.24M derived: sum of 2 quarters · filed 2026-02-19 | -$237.87M derived: sum of 3 quarters · filed 2026-02-19 | -$231.11M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | -$35.27M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | -$132.90M derived: sum of 2 quarters · filed 2026-02-19 | -$126.14M derived: sum of 3 quarters · filed 2026-02-19 | -$108.39M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$97.63M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$90.87M derived: sum of 2 quarters · filed 2024-11-18 | -$73.12M 10-Q/A · filed 2024-11-18 | -$59.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $6.76M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $24.51M 10-Q/A · filed 2024-11-18 | $38.51M derived: sum of 3 quarters · filed 2025-02-27 | $55.01M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $17.75M 10-Q/A · filed 2024-11-18 | $31.75M derived: sum of 2 quarters · filed 2025-02-27 | $48.25M derived: sum of 3 quarters · filed 2025-02-27 | $49.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $30.50M derived: sum of 2 quarters · filed 2025-02-27 | $31.25M derived: sum of 3 quarters · filed 2025-02-27 | $57.01M 10-K · filed 2025-02-27 |
| 2022-09-30 | $16.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $17.25M derived: sum of 2 quarters · filed 2023-11-09 | $43.01M 10-Q · filed 2023-11-09 | $52.67M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | $750.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $26.51M 10-Q · filed 2023-08-11 | $36.17M derived: sum of 3 quarters · filed 2024-11-18 | $41.95M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | $25.76M 10-Q · filed 2023-05-11 | $35.42M derived: sum of 2 quarters · filed 2024-11-18 | $41.20M derived: sum of 3 quarters · filed 2024-11-18 | -$6.16M derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | $9.66M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $15.44M derived: sum of 2 quarters · filed 2024-11-18 | -$31.92M derived: sum of 3 quarters · filed 2024-11-18 | -$22.62M 10-K/A · filed 2024-11-18 |
| 2021-09-30 | $5.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$41.58M derived: sum of 2 quarters · filed 2022-11-03 | -$32.28M 10-Q · filed 2022-11-03 | -$3.66M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | -$47.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$38.06M 10-Q · filed 2022-08-04 | -$9.44M derived: sum of 3 quarters · filed 2023-03-02 | -$3.65M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $9.30M 10-Q · filed 2022-05-05 | $37.92M derived: sum of 2 quarters · filed 2023-03-02 | $43.70M derived: sum of 3 quarters · filed 2023-03-02 | -$13.06M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $28.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $34.40M derived: sum of 2 quarters · filed 2023-03-02 | -$22.36M derived: sum of 3 quarters · filed 2023-03-02 | -$7.60M 10-K · filed 2023-03-02 |
| 2020-09-30 | $5.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$50.98M derived: sum of 2 quarters · filed 2021-11-04 | -$36.22M 10-Q · filed 2021-11-04 | -$25.90M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | -$56.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$42.01M 10-Q · filed 2021-08-05 | -$31.68M derived: sum of 3 quarters · filed 2022-03-08 | -$15.67M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $14.75M 10-Q · filed 2021-05-10 | $25.08M derived: sum of 2 quarters · filed 2022-03-08 | $41.09M derived: sum of 3 quarters · filed 2022-03-08 | -$922.00K derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | $10.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $26.34M derived: sum of 2 quarters · filed 2022-03-08 | -$15.68M derived: sum of 3 quarters · filed 2022-03-08 | -$1.74M 10-K · filed 2022-03-08 |
| 2019-09-30 | $16.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$26.00M derived: sum of 2 quarters · filed 2020-11-05 | -$12.06M 10-Q · filed 2020-11-05 | -$14.20M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | -$42.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$28.08M 10-Q · filed 2020-08-10 | -$30.21M derived: sum of 3 quarters · filed 2021-03-18 | -$28.81M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $13.94M 10-Q · filed 2020-05-07 | $11.80M derived: sum of 2 quarters · filed 2021-03-18 | $13.20M derived: sum of 3 quarters · filed 2021-03-18 | -$6.00M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | -$2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$733.00K derived: sum of 2 quarters · filed 2021-03-18 | -$19.93M derived: sum of 3 quarters · filed 2021-03-18 | -$15.23M 10-K · filed 2021-03-18 |
| 2018-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$17.80M derived: sum of 2 quarters · filed 2019-11-06 | -$13.10M 10-Q · filed 2019-11-06 | -$8.26M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | -$19.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$14.50M 10-Q · filed 2019-08-06 | -$9.65M derived: sum of 3 quarters · filed 2020-02-24 | |
| 2018-03-31 | $4.70M 10-Q · filed 2019-05-07 | $9.55M derived: sum of 2 quarters · filed 2020-02-24 | ||
| 2017-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | -$22.53M 10-K · filed 2020-02-24 | ||
| 2017-09-30 | -$27.37M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | -$12.08M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |